Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 132Carcinoma, Transitional Cell 91Carcinoma, Non-Small-Cell Lung 84Urinary Bladder Neoplasms 81Melanoma 75Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 49Colorectal Neoplasms 41Ovarian Neoplasms 36Stomach Neoplasms 35Triple Negative Breast Neoplasms 33Neoplasm Metastasis 32Uterine Cervical Neoplasms 31Neoplasms 28Kidney Neoplasms 27Breast Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Lung Neoplasms 26Pancreatic Neoplasms 23Carcinoma, Hepatocellular 23Esophageal Neoplasms 21Head and Neck Neoplasms 20Endometrial Neoplasms 18Small Cell Lung Carcinoma 16Carcinoma, Merkel Cell 11Mesothelioma 9Cholangiocarcinoma 9Ureteral Neoplasms 8Sarcoma 8Carcinoma, Ovarian Epithelial 8

Interventions

pembrolizumab 2enfortumab vedotin 2Nivolumab 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1relatlimab 1erdafitinib 1avelumab 1Vinblastine 1Specimen Handling 1Paclitaxel 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Urothelial Carcinoma × pembrolizumab × Genitourinary × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Hoosier Cancer Research Network

Phase 2 Recruiting
47 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡